MedTrace Logo

Efficacy of a Rehabilitation Program With the Pediatric Exoskeleton ATLAS 2030 in Pediatric Patients With Cerebral Palsy

NCT05926635 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2024-09-27

No results posted yet for this study

Summary

Cerebral Palsy (CP) is the first cause of motor disability in children worldwide. ATLAS 2030 is a robotic gait exoskeleton designed to rehabilitate children with motor disability. The objective of this study is to analyse the efficacy of a training program with ATLAS 2023 in chilren with CP.

Conditions

  • Cerebral Palsy

Interventions

DEVICE

ATLAS 2030

sessions of rehabilitation with the ATLAS 2030 exoskeleton twice per week as part of their routine rehabilitation

Sponsors & Collaborators

  • National Research Council, Spain

    collaborator OTHER_GOV

  • Hospital Infantil Universitario Niño Jesús, Madrid, Spain

    collaborator OTHER

  • Hospital Universitario La Paz

    collaborator OTHER

  • Hospital Universitario 12 de Octubre

    collaborator OTHER

  • Hospital General Universitario Gregorio Marañon

    collaborator OTHER

  • MarsiBionics

    lead INDUSTRY

Principal Investigators

  • Olga Arroyo Riaño · Hospital Universitario Gregorio Marañón

  • María Teresa Vara Arias · Hospital Infantil Universitario Niño Jesús

  • Ignacio Martínez Caballero · Hospital Infantil Universitario Niño Jesús

  • Sandra Espinosa García · Hospital Univsersitario La Paz

  • Sofía García de las Peñas · Hospital 12 de Octubre

  • Elena García Armada · National Research Council, Spain

Eligibility

Min Age
3 Years
Max Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-03
Primary Completion
2025-05-11
Completion
2025-05-11

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05926635 on ClinicalTrials.gov